So what kind of changes do we see in ACPA+ arthralgia patients, in the 6 months prior to them developing inflamm arthritis? - ACPA titre up, RF pos - EMS, pain up - ESR up Good things to keep an eye on in pre-RA Emery group POS1046 #EULAR2023 @RheumNow https://t.co/cSKPb5SbVH

‘Where have all the rheumatoid nodules gone?’ (Fantastic poster title @MayoClinic) Don’t get to see them much in clinic anymore. Almost surprised when I do Smoking is down Therapies are better RA is changing (a fact worth remembering!) POS1066 #EULAR2023 @RheumNow https://t.co/VxDNusIjOa

#EULAR2023 #POS1069 SLR & meta-analysis to inform EULAR Points to Consider which included 15 studies showed that targeted therapies were not associated with increased risk of cancer recurrence in patients with inflammatory arthritis AND a historyof cancer (85% had RA) @RheumNow https://t.co/uK2XHLjpj8

‘Clinically suspect arthralgias: fact or myth’ - a great debate topic #EULAR2023 First, the argument for. And we start with a reminder as to what we really mean by CSA @RheumNow https://t.co/e1CdxKi69m

“There was a time when a well-rounded physician had a good grounding in the humanities as well, and we lost that as more teaching time focused on understanding medical science and technology.” Brian Goldman @RheumNow https://t.co/tfXHPRJXAo

To treat or not? Clinically suspect arthralgia does affect QoL including function. Both premises of treating with a DMARD are valid. OverRx v missing the very early window of opportunity @RheumNow #EULAR2023 @eular_org https://t.co/86CVZ2IjEf

Use of antîmalarials in RA reduced the risk of bacterial infection in RA, smaller number of viral and fungal to study impact on systematic infections Bredemeier M, Abst#OP223 #EULAR2023 @RheumNow https://t.co/RXuFi3LdZC

Should we use #immunesuppression EARLY in #scleroderma to prevent #ILD? Answer from a study comparing Y vs N immune suppression- there was no difference in FVC decline. Maybe not a long enough study, ? Chanelling bias scleroderma #lung #disease OP0239 @RheumNow #EULAR2023

#EULAR2023 #POS1128 Promising new therapy on the block for #lupus nephritis. A single arm Phase 2a study showed Zetomipozomib, selective immunoproteosome-i + MMF showed about 2/3 pts met =>50% reduction in uPCR at WK24. No safety signal including low IgG or infection @RheumNow https://t.co/0A8cCW5GVV

50% reduction of RF levels & Complete seroconversion at M3 predicts LDA and Remission at M6 to M24 period after treatment initiation. RF responders reach LDA/Rem faster. Exciting data but... SDAI remains the stronger predictor of response at M3 @Rheumnow #EULAR23 OP0272 https://t.co/td1MZEzqag

We worried that JAKi + MTX might impair Shingrix efficacy, esp given JAKi HZ risk Shingrix nested in upa RCT: Response (seroconversion rate, titres, cellular response) less than gen pop, but still very good + only 2/95 had RA flares Vaccinate away! OP0225 #EULAR2023 @RheumNow https://t.co/i4ObRSyYh9

#ClinicalPearl Rx of #scleroderma #ILD -add another drug. MMF, then Cyclo, Rituximab, ?tocilizumab; if progressive fibrosis then #Nintedanib ?Pirfenidone Small RCT of MMF v Tacrolimus - looked the same -helpful if MMF fails, future pregnancy OP0240 @RheumNow #EULAR2023 @eular_org https://t.co/XWphyEO2JJ

Natural sequence of events happening in a subclinically inflamed joint, serial MRI study When progressing to clinical RA First osteitis then synovitis & tenosynovitis 🦴➡️✋ During resolution tenosynovitis reduces first then synovitis & osteitis @RheumNow #EULAR23 OP0261 https://t.co/ic94htYv6T

#EULAR2023 #POS1133 Consistent with clinical response in Phase 2 RCT, therapy with Updacitinib alone and ABV599-HD (Elsubrutinib + Upadacitinib) modulated IFN-I signalling pathways (IFN gene expression & proteomics). Assuring therapeutic evidence @RheumNowNews https://t.co/27mtCNg76X